Literature DB >> 15253274

Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice.

Stanley Kosanke1, Susan M Edgerton, Dan Moore, XiaoHe Yang, Terza Mason, Kathy Alvarez, Lynn Jones, Aeree Kim, Ann D Thor.   

Abstract

Phenotypic and biological heterogeneity was studied in a single transgenic mouse model to determine the level of biological variance. We analyzed 1,258 tumors from 417 MMTV-wt-ErbB-2 transgenic mice, subdivided by casein or soy-based dietary randomization and hormonal treatment. Variance in tumor histologic features, growth pattern, invasion, metastases, and multi-focality were detected in untreated and treated mice. Ninety-three percent (1,174/1,258) of tumors had the solid growth pattern widely reported in this model. However, among the solid tumors, a spectrum of growth patterns, from well-circumscribed tumors with a pseudocapsule to locally invasive or highly aggressive, metastatic subtype, was observed. Of the non-solid tumors, glandular features were prominent in 84 (7%). Adenocarcinomas included papillary, acinar/glandular, and adenosquamous subtypes. Adenosquamous tumors were exclusively observed in the group of mice treated on a short-term basis with estrogen. In contrast to the reported literature for this transgenic mouse model, mammary tumors were multifocal in the majority of cases (303 of 417 mice, or 73%). Results of this extensive study of a single transgenic model of mammary tumorigenesis indicate phenotypic and biological heterogeneity not previously associated with this transgenic mouse. These data support a complex, multistep process of carcinogenesis and clonal evolution, with biological and phenotypic variance similar to that observed in human mammary cancer development.

Entities:  

Mesh:

Year:  2004        PMID: 15253274

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  6 in total

1.  Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2.

Authors:  Robert K Dearth; Xiaojiang Cui; Hyun-Jung Kim; Isere Kuiatse; Nicole A Lawrence; Xiaomei Zhang; Jana Divisova; Ora L Britton; Syed Mohsin; D Craig Allred; Darryl L Hadsell; Adrian V Lee
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

2.  Morinda citrifolia (Noni) Juice Augments Mammary Gland Differentiation and Reduces Mammary Tumor Growth in Mice Expressing the Unactivated c-erbB2 Transgene.

Authors:  William P Clafshenkel; Tracy L King; Mary P Kotlarczyk; J Mark Cline; Warren G Foster; Vicki L Davis; Paula A Witt-Enderby
Journal:  Evid Based Complement Alternat Med       Date:  2012-04-26       Impact factor: 2.629

3.  Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.

Authors:  Aeree Kim; Bolin Liu; Dalia Ordonez-Ercan; Kathy M Alvarez; Lynn D Jones; Christine McKimmey; Susan M Edgerton; Xiaohe Yang; Ann D Thor
Journal:  Breast Cancer Res       Date:  2005-07-06       Impact factor: 6.466

4.  Recombinant Human Granulocyte Colony-Stimulating Factor Promotes Preinvasive and Invasive Estrogen Receptor-Positive Tumor Development in MMTV-erbB2 Mice.

Authors:  Chun Ling Zhao; Guang Ping Zhang; Zheng Zheng Xiao; Zhi Kun Ma; Cai Peng Lei; Shi Yuan Song; Ying Ying Feng; Ya Chao Zhao; Xiao Shan Feng
Journal:  J Breast Cancer       Date:  2015-06-26       Impact factor: 3.588

5.  Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer.

Authors:  Balasunder R Dodda; Corry D Bondi; Mahmud Hasan; William P Clafshenkel; Katie M Gallagher; Mary P Kotlarczyk; Shalini Sethi; Ethan Buszko; Jean J Latimer; J Mark Cline; Paula A Witt-Enderby; Vicki L Davis
Journal:  Front Oncol       Date:  2019-07-09       Impact factor: 6.244

6.  The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.

Authors:  Y Li; Y Zhang; J Hill; H-T Kim; Q Shen; R P Bissonnette; W W Lamph; P H Brown
Journal:  Br J Cancer       Date:  2008-03-25       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.